Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
May 25, 2021Frontiers in OncologyOpen Access

Immunotherapy in Treating EGFR-Mutant Lung Cancer: Current Challenges and New Strategies

View Full Paper
Ask AI
Bookmark
Share

Authors

KTKenneth K.W. ToWFWinnie FongWCWilliam C. Cho

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

To et al. (2021) studied this question.

synapsesocial.com/papers/69fcb9e070ef415335fa3e89https://doi.org/10.3389/fonc.2021.635007
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Programmed Death Ligand-1 Immunohistochemistry: Friend or Foe?2016 · 136 citations
  2. 2PD-L1 co-stimulation, ligand-induced TCR down-modulation and anti-tumor immunotherapy2012 · 46 citations
  3. 3Smokers or non-smokers: who benefits more from immune checkpoint inhibitors in treatment of malignancies? An up-to-date meta-analysis2020 · 98 citations
  4. 4PD-1/PD-L1 Blockade Therapy in Advanced Non-Small-Cell Lung Cancer: Current Status and Future Directions2019 · 415 citations
  5. 5Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors2019 · 1,177 citations